Burning Rock Reports Second Quarter 2026 Financial Results
Burning Rock Biotech reported Q2 2026 revenue of RMB134.7 million (US$19.9 million), down 9.3% year-over-year but up sequentially from RMB107.9 million in Q1, which management called the anticipated recovery from first-quarter order volatility. The mix was uneven: in-hospital revenue grew 7.4% YoY to RMB67.1 million, while central laboratory revenue fell 10.0% on the ongoing transition to in-hospital channels and pharma R&D services dropped 31.8% on lower testing volumes. Net loss widened to RMB18.4 million (US$2.7 million) from RMB9.7 million a year ago, with loss per share of RMB0.17 (US$0.02), though gross margin held near-flat at 72.6%.
Key figures
- Revenue
- 19862000
- Revenue Yoy
- -9.3%
- Revenue rmb
- 134765000
- Gross margin
- 72.6%
- Net loss rmb
- 18410000
- Net loss usd
- 2712000
- Gross profit rmb
- 97813000
- Non gaap gross margin
- 74.3%
- Pharma rnd revenue yoy
- -31.8%
- Central lab revenue yoy
- -10.0%
- In hospital revenue yoy
- +7.4%
- Net loss prior year rmb
- 9702000
- Cash restricted cash usd
- 61769000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.